PL1905452T3 - Środek do zapobiegania lub leczenia jaskry - Google Patents

Środek do zapobiegania lub leczenia jaskry

Info

Publication number
PL1905452T3
PL1905452T3 PL06780961T PL06780961T PL1905452T3 PL 1905452 T3 PL1905452 T3 PL 1905452T3 PL 06780961 T PL06780961 T PL 06780961T PL 06780961 T PL06780961 T PL 06780961T PL 1905452 T3 PL1905452 T3 PL 1905452T3
Authority
PL
Poland
Prior art keywords
glaucoma
prevention
agent
treatment
Prior art date
Application number
PL06780961T
Other languages
English (en)
Inventor
Ken Mizuno
Jiro Matsumoto
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of PL1905452T3 publication Critical patent/PL1905452T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06780961T 2005-07-12 2006-07-11 Środek do zapobiegania lub leczenia jaskry PL1905452T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005203352 2005-07-12
PCT/JP2006/313740 WO2007007737A1 (ja) 2005-07-12 2006-07-11 緑内障を予防又は治療する薬剤
EP06780961.6A EP1905452B1 (en) 2005-07-12 2006-07-11 Agent for prevention or treatment of glaucoma

Publications (1)

Publication Number Publication Date
PL1905452T3 true PL1905452T3 (pl) 2013-11-29

Family

ID=37637126

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06780961T PL1905452T3 (pl) 2005-07-12 2006-07-11 Środek do zapobiegania lub leczenia jaskry

Country Status (11)

Country Link
US (1) US8193193B2 (pl)
EP (1) EP1905452B1 (pl)
JP (1) JP4972552B2 (pl)
KR (1) KR101333990B1 (pl)
CN (1) CN101198355B (pl)
DK (1) DK1905452T3 (pl)
ES (1) ES2416334T3 (pl)
HR (1) HRP20130876T1 (pl)
PL (1) PL1905452T3 (pl)
PT (1) PT1905452E (pl)
WO (1) WO2007007737A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026664A1 (ja) 2005-08-30 2007-03-08 Asahi Kasei Pharma Corporation スルホンアミド化合物
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
CN101730690B (zh) 2007-07-02 2013-01-16 旭化成制药株式会社 磺酰胺化合物及其结晶
ES2684351T3 (es) * 2011-02-04 2018-10-02 Kowa Co., Ltd. Terapia farmacológica para prevenir o tratar glaucoma
JP2013129604A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する徐放性フィルム製剤
JP2013129605A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する安定なフィルム製剤
JP2015229671A (ja) * 2014-06-06 2015-12-21 株式会社デ・ウエスタン・セラピテクス研究所 網膜色素上皮細胞保護剤
US10034885B2 (en) 2014-09-24 2018-07-31 Kowa Company, Ltd. Corneal thickness modulating agent
PT3199161T (pt) * 2014-09-25 2022-02-08 Kowa Co Preparação farmacêutica
HUE048790T2 (hu) 2014-09-25 2020-09-28 Kowa Co Vizes készítmény
KR20160108121A (ko) 2015-03-06 2016-09-19 코와 가부시키가이샤 수성 조성물
TWI699207B (zh) * 2015-08-31 2020-07-21 日商興和股份有限公司 拉巴斯吉之用於製造眼壓下降增強劑之用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554816A (en) * 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
US3885047A (en) * 1972-06-16 1975-05-20 Mead Johnson & Co Ocular hypotensive process employing dextrorotatory phenethanolamines
US4483864A (en) * 1983-02-04 1984-11-20 University Of Iowa Research Foundation Non-classical topical treatment for glaucoma
JPS61227581A (ja) 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
JP4316794B2 (ja) 1997-10-22 2009-08-19 株式会社デ・ウエスタン・セラピテクス研究所 イソキノリン誘導体及び医薬
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
AU5198199A (en) 1998-08-17 2000-03-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
PT1270570E (pt) 2000-03-16 2006-10-31 Mitsubishi Pharma Corp Composto de amida e sua utilizacao
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment
US7442686B2 (en) * 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
MXPA04005674A (es) * 2001-12-12 2004-10-15 Pharmacia Corp Metodo para tratar trastornos oftalmicos con antagonistas epoxi-esteroidales del receptor de aldosterona.
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
WO2003062227A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
EP1515974A4 (en) * 2002-06-17 2007-02-28 Merck & Co Inc NOVEL MAXI K CHANNEL BLOCKERS, METHODS OF USE, AND METHODS OF MANUFACTURING THE SAME
JP4482726B2 (ja) * 2002-08-29 2010-06-16 参天製薬株式会社 Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
AU2003257588A1 (en) * 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
CA2400996A1 (en) 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
WO2004039796A1 (de) 2002-10-28 2004-05-13 Bayer Healthcare Ag Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
WO2004045644A1 (ja) 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
JP2004250410A (ja) 2003-02-21 2004-09-09 Mitsubishi Pharma Corp 腎臓における虚血−再灌流障害の治療剤
EP1606266A4 (en) 2003-03-21 2008-06-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
WO2005037197A2 (en) 2003-10-06 2005-04-28 Glaxo Group Limited Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
US20070123561A1 (en) 2003-10-06 2007-05-31 Dennis Lee Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors
JP2007507549A (ja) 2003-10-06 2007-03-29 グラクソ グループ リミテッド キナーゼ阻害剤としての1,6,7−三置換アザベンゾイミダゾールの調製
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
JP2007015928A (ja) 2003-10-15 2007-01-25 Ube Ind Ltd 新規オレフィン誘導体
WO2005099691A1 (en) * 2004-03-31 2005-10-27 Pharmacia & Upjohn Company Llc Composition for treating elevated intraocular pressure
CA2583593A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20060142270A1 (en) * 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma

Also Published As

Publication number Publication date
KR101333990B1 (ko) 2013-11-27
EP1905452B1 (en) 2013-06-19
CN101198355A (zh) 2008-06-11
ES2416334T3 (es) 2013-07-31
US20090118299A1 (en) 2009-05-07
EP1905452A4 (en) 2012-02-15
CN101198355B (zh) 2010-11-10
JPWO2007007737A1 (ja) 2009-01-29
PT1905452E (pt) 2013-07-16
HRP20130876T1 (hr) 2013-10-25
KR20080027827A (ko) 2008-03-28
JP4972552B2 (ja) 2012-07-11
EP1905452A1 (en) 2008-04-02
DK1905452T3 (da) 2013-07-01
US8193193B2 (en) 2012-06-05
WO2007007737A1 (ja) 2007-01-18

Similar Documents

Publication Publication Date Title
PL1905452T3 (pl) Środek do zapobiegania lub leczenia jaskry
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
IL191283A (en) Compositions for treating eye irregularities
IL187999A0 (en) Compositions for the treatment of persistent infections
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
IL190779A0 (en) Compositions for treatment of eye diseases
PL1884234T3 (pl) Środek profilaktyczny lub leczniczy w zaburzeniach rogówkowych i spojówkowych
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
EP1950209A4 (en) TREATMENT AGENT FOR CIRCULATORY INSUFFICIENCY
EP1915998A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL OR CONJUNCTIVAL DISEASE
GB0909297D0 (en) Composition for the treatment of skin conditions
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
PL2056799T3 (pl) Kompozycje i sposoby do leczenia lub zapobiegania jaskrze lub jej rozwojowi
IL188787A (en) Preparations for the treatment of diabetic eye complications
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
EP1799849A4 (en) AGENTS FOR THE TREATMENT OR PREVENTION OF ALLERGIC DISEASES
EP1857119A4 (en) AGENT FOR THE PREVENTION / TREATMENT OF NEURODEGENERATIVE DISEASE
EP1865952A4 (en) COMPOSITIONS CONTAINING HISTAMINES FOR THE TREATMENT OF ALLERGIES
HUP0500947A2 (en) Composition for treatment of paradontosis
ZA200903626B (en) DMAE as sole agent for the treatment of mild cognitive impairment